Clinical utility and cost of non-invasive prenatal testing

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 27, Issue 3, 2014, Pages 320-321

  Cuckle, Howard ^a   Benn, Peter ^b   Pergament, Eugene ^c  

^a Department of Medicine   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c Northwestern Reproductive Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOWN SYNDROME; FALSE POSITIVE RESULT; GENETIC SCREENING; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; LETTER; MATERNAL AGE; PRENATAL SCREENING; PREVALENCE; PRIORITY JOURNAL;

DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; MATERNAL SERUM SCREENING TESTS; PREGNANCY; PRENATAL DIAGNOSIS; SEQUENCE ANALYSIS, DNA;

EID: 84891939325     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2013.807239     Document Type: Letter

References (5)

1. Song K, Musci T, Caughey AB. Clinical utility and cost of noninvasive prenatal testing with cfDNA analysis in high risk women based on a U.S. population. J Matern Fetal Neonatal Med 2013;26:1180-5.
2. Dan S, Wang W, Ren J, et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11, 105 pregnancies with mixed risk factors. Prenat Diagn 2012;32:1225-32.
3. Sahota DS, Leung WC, Chan WP, et al. Prospective assessment of the Hong Kong Hospital Authority universal Down syndrome screening programme. Hong Kong Med J 2013;19:101-8.
4. Cuckle H, Benn P. Multianalyte maternal serum screening for chromosomal defects. In: Milunsky A, Milunsky JM, eds. Genetic disorders and the fetus: diagnosis, prevention and treatment. 6th ed. Baltimore: Johns Hopkins University Press; 2010:771-818.
5. Martin JA, Hamilton BE, Ventura SJ, et al. Births: final data for 2010. Natl Vital Stat Rep 2012;61:1-72.